Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Nick80on Sep 10, 2021 11:04am
244 Views
Post# 33839700

RE:RE:RE:IBD update ... market size

RE:RE:RE:IBD update ... market sizeI agree with you that this is the pathway any company should take to spread the risk.

In hindsight I wish I invested only 1k since the focus was for a long time only on one drug and it appears to me that mgtm is scrambling and backtracking to broaden their opportunities now as they realize that 346 might not become the blockbuster drug they promoted. 

That said you are right lets see what the october update is. I hope its positive but have no more expectations for this company. 

As an investore I should have closer looked at their strategy and minimized risk by waiting for results first and minimizing my position at the hype since they did not invest enough in other candidates in parallel. 

Overall I am quite disappointed mostly at myself for being to hopefull instead of cautious. 

That being said lets see what October brings - iI don't anticipate life changing news then eiter but at this point the hope dies last...
<< Previous
Bullboard Posts
Next >>